Myasthenia as a paraneoplastic manifestation of ovarian Cancer

Affiliations

Case Reports

Marcelo Simonsen et al. Gynecol Oncol Rep. 2018.

. 2018 May 15:25:35-36.

doi: 10.1016/j.gore.2018.05.008. eCollection 2018 Aug.

Erratum in

Erratum regarding missing Declaration of Competing Interest statements in previously published articles.
[No authors listed] [No authors listed] Gynecol Oncol Rep. 2021 Jan 18;35:100703. doi: 10.1016/j.gore.2021.100703. eCollection 2021 Feb. Gynecol Oncol Rep. 2021. PMID: 33614877 Free PMC article.

We describe the first case of myasthenia gravis as a possible paraneoplastic manifestation of ovarian cancer preceding its diagnosis.

Keywords: Diagnosis; Myasthenia gravis; Ovarian neoplasm; Paraneoplastic disorders; Treatment.

1. Caliandro P., Luigetti M., Ricci E., Mirabella M., Tonali P.A., Padua L. Cerebellar degeneration and ocular myasthenia gravis in a patient with recurring ovarian carcinoma. Neurol. Sci. 2010;31(1):79–81. - PubMed
1. Dalmau J., Rosenfeld M.R. Update on paraneoplastic neurologic disorders. Commun. Oncol. 2010;7(5):219–224. - PMC - PubMed
1. Giometto B., Grisold W., Vitaliani R., Graus F., Honnorat J., Bertolini G. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch. Neurol. 2010;67(3):330–335. - PubMed
1. Graus F., Delattre J.Y., Antoine J.C., Dalmau J., Giometto B., Grisold W. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry. 2004;75(8):1135–1140. - PMC - PubMed
1. McGuire W.P., Hoskins W.J. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. England J. Med. 1996;334(1):1–6. - PubMed